Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation, Confirmation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of TH9619 in Subjects With Advanced Solid Tumors

NCT07151040 is registered in ClinicalTrials.gov with One-carbon Therapeutics AB as lead sponsor.

NCT NCT07151040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07151040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation, Confirmation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of TH9619 in Subjects With Advanced Solid Tumors
Lead sponsor
One-carbon Therapeutics AB
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 22, 2025
Completion date
December 31, 2026
Enrollment
43 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer (crc), gastric cancer, gastrooesophageal junction cancer, non-small cell lung cancer (nsclc), solid tumor, squamous cell carcinoma of head and neck